Emergent BioSolutions (EBS) Stock Analysis & AI Equity Report

Medical - Pharmaceuticals USD Explore free reports

Emergent BioSolutions (EBS) overview

Emergent BioSolutions (EBS) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 743m and operating profit of USD 100m; the year-end share price was 12.36 USD and market capitalisation was USD 644m. Emergent BioSolutions is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Emergent BioSolutions's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 523mFY 2025
Share price12.36 USDFY 2025 year end
RevenueUSD 743mFY 2025
Operating profitUSD 100mFY 2025
Net earningsUSD 52.6mFY 2025
Market capitalisationUSD 644mFY 2025 year end

About Emergent BioSolutions

Emergent BioSolutions develops and supplies products and services addressing public health threats, including chemical, biological, radiological and nuclear threats, emerging infectious diseases, health crises, and emergency care. Its portfolio includes naloxone nasal sprays, anthrax and smallpox medical countermeasures, and contract development and manufacturing services. Customers include government agencies, pharmacies, health departments, law enforcement, and community organizations.

Generate the Emergent BioSolutions report

Emergent BioSolutions is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Emergent BioSolutions and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Emergent BioSolutions

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.